Evidence map›Paper›PMID 40189807›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Brain cholinergic terminal density utilizing [

Jason K Russell, Alexander C Conley, Brian D Boyd, John Patrick Begnoche, Rachel Schlossberg, Allison Stranick, Adam J Rosenberg, Lealani Mae Y Acosta, Dann Martin, Yasmeen Neal and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Brain cholinergic terminal density utilizing [Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jason K RussellCenter for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0001-6263-1674
Alexander C ConleyCenter for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Brian D BoydCenter for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
John Patrick BegnocheCenter for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Rachel SchlossbergCenter for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Allison StranickCenter for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Adam J RosenbergVanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Lealani Mae Y AcostaDepartment of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Dann MartinDepartment of Clinical Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Yasmeen NealCenter for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Michael S RafiiAlzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, California, USA.
Julie DumasDepartment of Psychiatry, University of Vermont, Burlington, Vermont, USA.
Paul A NewhouseCenter for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Funding

The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Overall: Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Center at VanderbiltP50HD103537 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Jeffrey L Neul · 2020 to 2026
$10.3M
Health of the Cholinergic System and Risk for Alzheimer's Disease in Postmenopausal WomenR01AG066159 · NIA · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI DUMAS, JULIE A, NEWHOUSE, PAUL A. · 2019 to 2023
$7.9M
Clinical trials to prevent Alzheimer's Disease in Down SyndromeR33AG066543 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI RAFII, MICHAEL S · 2022 to 2024
$6.9M
Replacement and Upgrade of a 3T MR Scanner for ResearchS10OD021771 · OD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GORE, JOHN C · 2016 to 2016
$2.0M
A PET-CT Scanner for Translational ResearchS10OD012297 · OD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GORE, JOHN C · 2015 to 2015
$2.0M
The cholinergic integrity in Down syndrome in association with aging, Alzheimer's disease pathology, and cognitionR21AG075643 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI NEWHOUSE, PAUL A. · 2022 to 2022
$476k
cGMP Compliant HPLC for Radiopharmaceutical Quality ControlS10OD032383 · OD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PETERSON, TODD E · 2022 to 2022
$91k
Alzheimer's Association AARG-21-850839Eunice Kennedy Shriver National Institute of Child Health and Human Development 1P50HD103537-01Foundation for the National Institutes of Health 1S10OD021771-01Foundation for the National Institutes of Health 1S10OD032383Foundation for the National Institutes of Health S10OD012297NCATS NIH HHS 2UL1TR000445NCATS NIH HHS UL1 TR000445NIA NIH HHS R01 AG066159NIA NIH HHS R01AG066159NIA NIH HHS R21 AG075643NIA NIH HHS R21AG075643NIA NIH HHS R33AG066543NICHD NIH HHS P50 HD103537NIH HHS S10 OD012297NIH HHS S10 OD021771NIH HHS S10 OD032383
6 · The paper itself

Abstract

backgroundAdults with Down syndrome (DS) have increased risk of Alzheimer's disease (AD). The cholinergic system declines in AD, underlying many cognitive deficits. We investigated the relationship between amyloid accumulation and cholinergic terminal density in adults with DS compared to amyloid-matched controls.

methodsA total of 15 non-demented adults with DS and 15 amyloid-matched healthy controls were assessed for [

resultsAdults with DS displayed greater [ DISCUSSION: Adults with DS display higher [ HIGHLIGHTS: Adults with DS display greater cholinergic terminal density in specific ROIs than amyloid-match controls. Adults with DS exhibit a similar pattern of cholinergic terminal density across the brain. The first association of cholinergic terminal density with AD pathology in non-demented adults with DS. Adults with DS display a greater cholinergic terminal decline in association with amyloid accumulation than neurotypically developed age-matched controls. Region-specific cholinergic terminal density associated with cognitive performance in adults with DS.

Indexed as

AmyloidBrainCognitionDown SyndromePositron-Emission TomographyAdultAgedFemaleHumansMaleMiddle AgedNeuropsychological TestsPiperidinesAmyloidfluoroethoxy-benzovesamicolPiperidines[18F]‐FEOBVacetylcholineamyloidcholinergiccognitionDown syndromePET imaging

Identifiers

PMID40189807
PMCPMC11972980

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.